论文部分内容阅读
目的：观察骨化三醇口服治疗血液透析病人继发性甲状旁腺功能亢进（ＳＨＰＴ）的疗效。方法：４５例维持性血透病人中，１９例用小剂量骨化三醇（２μｇ×２次／ｗｋ）口服治疗，１１例用大剂量骨化三醇（４μｇ×２次／ｗｋ）口服治疗，１５例用骨化三醇０．２５μｇ／ｄ的常规小剂量治疗，疗程１６ｗｋ。结果：骨化三醇口服治疗后，ＳＨＰＴ明显降低（Ｐ＜０．０５，０．０１），骨密度明显增高（Ｐ＜０．０１），常规小剂量治疗病人中的ＳＨＰＴ值及骨密度则无显著变化（Ｐ＞０．０５）。结论：大剂量和小剂量骨化三醇口服治疗效果均优于常规小剂量治疗，其中大剂量比小剂量疗效好。
Objective: To observe the efficacy of calcitriol oral hemodialysis patients with secondary hyperparathyroidism (SHPT). METHODS: Of the 45 patients with maintenance hemodialysis, 19 were treated orally with low-dose calcitriol (2 μg × 2 times / wk) and 11 were orally administered with high-dose calcitriol (4 μg × 2 times / wk) , 15 cases with calcitriol 0.25μg / d routine small dose treatment, treatment 16wk. Results: SHPT was significantly decreased (P <0.05, 0.01) and bone mineral density was significantly increased (P <0.01) after oral calcitriol treatment. The SHPT value and bone mineral density No significant change (P> 0.05). Conclusion: The effects of high-dose and low-dose calcitriol oral treatment are better than the conventional low-dose treatment, of which large dose than small dose curative effect.